4 Cash-Heavy Large Cap Biotech Stocks That Analysts Rate As Buy

Some investors consider investing in biotech too risky. But focusing on large cap stocks and those that have ample cash reserves are some ways for reducing exposure. When a company is at the large cap level, it has already passed through several rounds of growth and weathered market upheavals. Additionally, having a high level of liquidity is a key asset when contemplating biotech stocks. Cash allows these companies to continue research and development, make strategic acquisitions, and expand to new territories. Our list today of large cap biotechnology stocks all have strong cash reserves and have recent 'Buy' ratings from industry analysts. We think you will be intrigued by our findings.The Current Ratio is a liquidity ratio used to determine a company's financial health. The metric illustrates how easily a firm can pay back its short obligations all at once through current assets. A company that has a current
... Read the rest at SeekingAlpha.com